(Reuters) - Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's ...

BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its Real-Time qPCR ...

PLEASANTON — Bio-Rad Laboratories, setting the stage for a big expansion in the East Bay, has bought a two-building complex in Pleasanton’s Hacienda Business Park to accommodate plans for more workers ...

(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...

Bio-Rad Laboratories (BIO) has seen its stock edge upward over the past week, catching some attention among investors. Shares closed at $297.95, reflecting modest gains that contrast with longer-term ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on October 23 and set a price target of $446.00. The company’s shares closed yesterday at ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...